∙ Ocular Inclusion Criteria:

• Diagnosis of nAMD prior to screening as determined by the investigator

• Difference of \<10% in ECD at screening between the 2 eyes as measured by specular microscopy and determined by the independent reading center

• Availability of historical visual acuity (VA) data and spectral-domain optical coherence tomography (SD-OCT). Additionally, fluorescein angiography or color fundus photography can both be used to support participant eligibility per protocol at investigator discretion

• Availability of comprehensive historical anti-vascular endothelial growth factor (VEGF) injection data, including agent administered and date of administration from the time of diagnosis, or for at least 2 years prior to screening if diagnosis was made more than 2 years before screening

• Response to at least two prior anti-VEGF IVT injections as determined by the investigator based on the following:

‣ Overall decrease in nAMD disease activity detected on historical or screening OCT

⁃ Stable or improved best-corrected visual acuity (BCVA)

• BCVA of 34 letters (approximate 20/200 Snellen equivalent) or better, using Early Treatment of Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters at screening and enrollment

• All subtypes of nAMD lesions are permissible

• nAMD lesions at the time of diagnosis must involve the macula

• Sufficiently clear ocular media and adequate pupillary dilation to allow for clinical examination and analysis and grading by the central reading center of SD-OCT images